To access this element change to forms mode OFF
Grant Award View - GA259016
Epigenetic Protection Predicts Risk Diabetic Nephropathy (EPICENTRE)
GA ID:
GA259016
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Mar-2022
Publish Date:
25-Jul-2022
Category:
Medical Research
Grant Term:
1-Jul-2022 to 30-Jun-2027
Value (AUD):
$4,897,328.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Clinical Trials and Cohort Studies
Grant Activity:
Epigenetic Protection Predicts Risk Diabetic Nephropathy (EPICENTRE)
Purpose:
Diabetes affects over 1 million Australians and disproportionately affects Indigenous Australians. We have established an international EPICENTRE consortium now seek to explore the potential role of epigenetic modifications to explain the development of diabetic renal disease. Over the last decade we have developed contemporary genomic technologies and new approaches that specifically characterise epigenetic modifications using overt renal disease as the primary outcome.
GO ID:
GO Title:
NHMRC Clinical Trials and Cohort Studies Grants 2021 for funding mid-2022
Internal Reference ID:
2022/GNT2014763
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC
Postcode:
Multiple
Country:
AUSTRALIA